menu close
eikontx.com
Eikon Therapeutics Inc-Logo

Eikon Therapeutics IPO

NASDAQ: EIKN

Company Profile:

Eikon Therapeutics completed their IPO on February 5, 2026. Now that Eikon Therapeutics is a public company, Nasdaq Private Market does not actively track its performance. The data below is for reference before the company’s IPO.

Eikon Therapeutics is a biotechnology company focused on pioneering new methods of drug discovery through advanced imaging techniques. Eikon aims to revolutionize the understanding of protein dynamics and their implications for therapeutic development.

Sign up for SecondMarket® to invest in or sell private companies like Eikon Therapeutics before their IPO.
Buy + Sell
  • Headquarters: Roseland, NJ
  • Year Founded: 2019
  • Sector: Health Care
Leverage Your Equity to Help Achieve More.

Eikon Therapeutics Funding Pre-IPO

Gain insights into Eikon Therapeutics funding history prior to their IPO, including the funding round, time period, and amount raised.

Sign Up to Unlock the Data
Financing Round Date Amount Price per share* Valuation*
Series B Feb 26, 2025 351.00M
Price
Valuation
Series C May 18, 2023 140.76M
Price
Valuation
Series B Dec 03, 2021 517.76M
Price
Valuation
Series A May 04, 2021 48.00M
Price
Valuation
Series A May 04, 2021 107.81M
Price
Valuation

*Access the PPS, Valuation details, and a wealth of other data by signing up. Source: Nasdaq Private Market Tape D®

Leverage Your Equity to Help Achieve More.

Eikon Therapeutics Management Team - Prior to IPO

  • Board Member

    Dror Berman

  • Chief Information Officer

    Ashish Kheterpal

  • President, Board Member

    Leon Chen

  • Board Member

    James Tannanbaum

  • COO

    Mike Klobuchar

  • CTO

    Russ Berman

  • Board Member

    Josh Wolfe

  • Chief Scientific Officer

    Dan Anderson

  • Board Member

    Robin Washington

  • Co-Founder

    Xavier Darzacq

  • Co-Founder

    Robert Tjian

  • Chief Business Officer

    Benjamin Thorner

  • Chief People Officer

    Barbara Howes

  • CEO, Director

    Roger Perlmutter

  • Board Member

    Kenneth Frazier

  • Chief Medical Officer

    Roy Baynes

  • CFO

    Alfred Bowie

  • Co-Founder

    Eric Betzig

Eikon Therapeutics Major Investors - Prior to IPO

  • Column Group

  • UC Investments (UCOP)

  • Horizon Ventures

  • E15 VC

  • AME Cloud Ventures

  • Hartford HealthCare Endowment

  • T. Rowe Price

  • Lux Capital

  • StepStone Group

  • Harel Insurance Investements & Financial Services

  • Foresite Capital

  • Innovation Endeavors

  • General Catalyst

  • Canada Pension Plan Investment Board (CPPIB)

  • Soros Fund Management

  • Abu Dhabi Investment Authority (ADIA)

  • EcoR1 Capital

  • Schroders Capital

Learn More About Eikon Therapeutics Stock

Buy Eikon Therapeutics Stock
01

Eikon Therapeutics became publicly traded following its IPO on February 5, 2026, its shares now trade on public stock exchanges under the ticker symbol NASDAQ: EIKN. Before the IPO, Eikon Therapeutics stock was privately held and available only through private market transactions.

If you’re an accredited investor looking to purchase pre-IPO shares in a private company, Nasdaq Private Market can help you get started. Learn more about investing in the private market or sign up for free to explore available opportunities. Learn more about how private company shares trade prior to an IPO on our investors page.

Sell Eikon Therapeutics Stock
02

Following its IPO on February 5, 2026, Eikon Therapeutics shares trade on public stock exchanges, allowing shareholders to sell stock through a traditional brokerage.

If you currently hold shares in a private company, Nasdaq Private Market may be able to help you explore your sell private company stock. Our platform provides a secure and compliant way to sell your shares on terms that work for both you and the company. To understand how employees sell shares before a company goes public, visit the Employee Shareholders page.

Eikon Therapeutics Stock Price
03

Following the IPO, Eikon Therapeutics stock prices can now be viewed publicly on major exchanges. Investors and interested parties can find the current stock price by searching Eikon Therapeutics’s ticker symbol on financial platforms such as Nasdaq.com or through their preferred brokerage platform.

Eikon Therapeutics Stock Ticker Symbol
04

Following its IPO on February 5, 2026, Eikon Therapeutics stock now trades on public markets under the ticker symbol NASDAQ: EIKN. You can view real-time stock information through widely used financial data platforms.

Criteria to Sell Eikon Therapeutics Stock
05

Following the Eikon Therapeutics IPO, public shares can be sold through any brokerage.

Nasdaq Private Market works with employees, ex-employees, and other private company shareholders of pre-IPO companies to sell their shares. The Nasdaq Private Market platform provides a secure and compliant way to sell your shares on terms that work for both you and the company. To learn more about how to sell private company stock, visit the Employee Shareholders page.

Read more about how to sell shares of a private company and eligibility for selling privately held stock:

Criteria to Buy or Invest in Eikon Therapeutics Stock
06

Following Eikon Therapeutics’s initial public offering on February 5, 2026, its shares are now listed on a public exchange and available for purchase through a brokerage account. Investors interested in buying Eikon Therapeutics stock can do so through their preferred broker, just as they would with any other publicly traded security.

Nasdaq Private Market continues to work with investors seeking exposure to private company opportunities prior to IPO. Through structured transactions and curated offerings, investors can participate in private market activity before companies enter the public markets.

Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.

Eikon Therapeutics Stock Settlement
07

Since Eikon Therapeutics is now publicly traded, public-market share transfers and settlement occur automatically through a brokerage or exchange.

Nasdaq Private Market supports transfer and settlement for privately held company equity. In order to buy or sell private company stock, share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patented Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.

To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.

Eikon Therapeutics IPO
08

Eikon Therapeutics completed its IPO on February 5, 2026, and is now publicly available through major financial sources.

Sign up for SecondMarket® to invest in or sell private companies like Eikon Therapeutics before their IPO.
Buy + Sell

*All trademarks are the property of their respective owner(s). Unless expressly stated otherwise, companies listed on this site are not sponsoring, endorsing, or otherwise affiliated with, Nasdaq Private Market, LLC, and none of the statements on this website should be attributed to a listed company.

Other Companies

Cerebral

Telemedicine mental health startup, providing evidence-based therapeutic techniques and medication management.

Color-Logo

Color Genomics

Physician-ordered genetic testing with comprehensive support, utilizing advanced software and a certified laboratory.

Roman Health Ventures-Logo

Ro

Healthcare technology for a patient-centric healthcare system.

Hinge Health-Logo

Hinge Health

Digital clinic for back, joint, and muscle pain.

Somatus-Logo

Somatus

Integrated care for patients with or at risk of developing kidney disease.

Cityblock Health-Logo

Cityblock Health

Tech-driven care provider for communities with complex needs.

Arsenalbio-Logo

ArsenalBio

Develops programmable cell therapies for cancer patients.

Rakuten Medical-Logo

Rakuten Medical

Developing precision, cell-targeting investigational therapies on its Illuminox platform, which have shown rapid and selective cell killing and tumor necrosis in pre-clinical studies.

Tessera Therapeutics-Logo

Tessera Therapeutics

Genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source.

Source: Nasdaq Private Market Tape D®